Lung Cancer

The appearance of a rash in cancer patients treated with erlotinib (Tarceva) is strongly associated with longer survival, according to researchers from the drug's developer, OSI Pharmaceuticals

Swiss drug regulators have become the first to approve Novartis' Tasigna (nilotinib) for the treatment of patients with Ph+ chronic myeloid leukemia who are resistant or intolerant to imatinib (Gleevec)

Breast cancer is the most commonly diagnosed cancer in women and is the second leading cause of cancer-related mortality, after lung cancer. The overall incidence of breast cancer was increasing until recently, but mortality has declined since 1990, presumably due to earlier detection and better treatments.

A global phase III study is the second to show that adding bevacizumab (Avastin) to chemotherapy extends progression-free survival (PFS) in patients with advanced non-small-cell lung cancer (NSCLC)

In an ongoing phase I trial in patients with solid tumors and lymphomas, the small-molecule tumor vascular disrupting agent NPI-2358 (Nereus Pharmaceuticals, San Diego, California) was dose escalated without evidence of dose-limiting toxicity

FDA has granted priority review for GlaxoSmithKline's new drug application (NDA) for Oral Hycamtin (topotecan) capsules for the treatment of relapsed small-cell lung cancer (SCLC)

The US Food and Drug Administration (FDA) has accepted, for filing and priority review, the New Drug Application (NDA) for Bristol-Myers Squibb's investigational compound ixabepilone, an epothilone B analog.

Cell Therapeutics, Inc (CTI) announced that data presented at the 2007 Annual Meeting of the American Society for Clinical Oncology (ASCO), held in Chicago on June 1-5, provides independent supportive data validating the potential survival benefit of paclitaxel poliglumex (Xyotax) over standard chemotherapy in the treatment of advanced non-small-cell lung cancer (NSCLC) in women whose estrogen levels are in the normal range for premenopausal women.

Although any steps taken to prevent cancer require many years before they influence outcomes, clinical investigators typically do not consider the time lag needed for prevention to elicit a measurable effect on life and health, opting instead to assess mortality in the short term

Brain metastasis can be prevented in advanced small-cell lung cancer (SCLC) patients by prophylactic cranial irradiation (PCI) in those who respond to chemotherapy

While pharmaceutical companies are actively engaged in the development of new drug treatments for cancer, the number of drugs eventually approved by the US Food and Drug Administration for oncology has declined.

A triplet that includes the investigational agent canfosfamide (Telcyta, Telik, Inc.) showed strong activity as first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC)

The third-generation epothilone KOS-1803 may optimize tumor penetration while limiting exposure to other tissues

It may someday be possible to identify patients at high risk of developing lung cancer by examining their exhaled breath

Approximately one-third of patients with non-small cell lung cancer (NSCLC) present with locally advanced disease, the majority of whom are treated with concurrent chemotherapy and thoracic radiation therapy. Concurrent chemoradiation therapy is superior to sequential chemotherapy followed by thoracic radiation therapy or thoracic radiation therapy alone.

This year's plenary presentations at the American Society of Clinical Oncology annual meeting, held in Chicago on June 1-5, addressed a variety of issues in five major cancer types.

Aranesp (darbepoetin alfa, Amgen) significantly reduced red blood cell (RBC) transfusions and did not affect overall or progression-free survival, compared with placebo, in a randomized, double-blind, phase III trial in 600 patients with previously untreated extensive-stage small-cell lung cancer receiving platinum-based chemotherapy.

Lung cancer remains the leading cause of cancer-related mortality in the United States. The predominant histologic type of lung cancer is Non-Small-Cell lung cancer (NSCLC). Approximately 30% of newly diagnosed patients with NSCLC present with stages I-IIIA disease.

University of Alberta researchers, led by Evangelos Michelakis, MD, have shown that dichloroacetate (DCA), added to the drinking water of nude athymic rats implanted with human lung cancer cells (A549), significantly reduced tumor size, compared with controls, and was associated with increased apoptosis and decreased proliferation.

Although CT screening increases the rates of lung cancer diagnosis and treatment among long-time smokers, data from three studies, individually and combined, show no evidence that such scanning reduces deaths from the disease

Long-term, high-level exposure to bacterial endotoxins in raw cotton fiber and cotton dust was associated with a 40% decrease in lung cancer risk among female Chinese textile workers. The risk of developing lung cancer decreased for workers exposed to greater amounts of endotoxins over many years.

AstraZeneca has initiated a new phase III study of its investigational once-daily oral agent vandetanib (Zactima, ZD6474), known as Study 36.

From 85% to 91% of cancer cases identified by annual CT lung screening in high-risk patients were early stage

Erlotinib (Tarceva) showed activity and was "relatively well tolerated" in chemotherapy-naive elderly patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)

Roche has announced that the international phase III Avastin in Lung study (AVAiL, BO17704) met its primary endpoint of improving progression-free survival in patients with previously untreated advanced non-squamous-cell, non-small-cell lung cancer (NSCLC).